Skip to main content

Abstract

In the International Germ Cell Cancer Consensus Group (IGCCCG) classification, a poor-risk group is defined as either having a mediastinal primary NSGCT, extra-pulmonary visceral metastases or very high serum tumour marker levels (hCG > 50,000 UI/L, AFP > 10,000 ng/mL and/or LDH > 10 times the upper limit value). This subgroup of 10% patients is responsible for most of the deaths from GCT. Their progression-free survival rate is 41 % with only half of them achieving long-term overall survival. Four cycles of the BEP regimen (cisplatin, etoposide and bleomycin), followed by resection of residual masses, became standard treatment for this group in 1987. After a period of 25 years during which all attempts to improve the results of BEP failed, the paradigm changed in 2014 with the use of personalized chemotherapy based on tumour marker decline. That a slow decline in hCG and AFP after the first cycle of BEP chemotherapy can single out patients likely to fail conventional therapy was demonstrated retrospectively and then confirmed prospectively. In the international GETUG-13 trial, once patients had received one cycle of BEP, patients with a favourable tumour marker decline continued BEP and patients with an unfavourable decline were randomised to receive either BEP or a 6-drug dose-dense regimen, including the BEP regimen drugs plus paclitaxel, oxaliplatin, and ifosfamide, with G-CSF support. The primary endpoint of progression-free survival in patients with an unfavourable tumour marker decline receiving dose-dense chemotherapy was improved: 59 % [95 % confidence interval (CI): 49–68] versus 48 % [95 % CI: 38–59] (p = 0.05; HR: 0.66 [0.44–1.00]).The overall probability of curing patients with poor-risk NSGCT managed according to this algorithm (BEP for patients with a favourable decline and dose-dense chemotherapy for patients with an unfavourable decline) now exceeds 75 %. Finally, more and more data support the need to centralise the care of patients with poor-risk NSGCT, and some countries have already implemented this policy at national level.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013;24:878–88.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28:4906–11.

    Article  Google Scholar 

  3. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–40.

    Article  CAS  PubMed  Google Scholar 

  4. Ozols RF, Ihde DC, Marston Linehan W, et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988;6:1031–40.

    CAS  PubMed  Google Scholar 

  5. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991;9:1163–72.

    CAS  PubMed  Google Scholar 

  6. Droz JP, Kramar A, Biron P, et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol. 2007;51:739–46.

    Article  CAS  PubMed  Google Scholar 

  7. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–56.

    Article  CAS  PubMed  Google Scholar 

  8. Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22:1054–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16:1287–93.

    CAS  PubMed  Google Scholar 

  10. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998;16:692–701.

    CAS  PubMed  Google Scholar 

  11. Culine S, Kramar A, Théodore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol. 2008;26:421–7.

    Article  CAS  PubMed  Google Scholar 

  12. Toner GC, Geller NL, Tan C, et al. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res. 1990;50:5904–10.

    CAS  PubMed  Google Scholar 

  13. Olofsson SE, Tandstad T, Jerkeman M, et al. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol. 2011;29:2032–9.

    Article  PubMed  Google Scholar 

  14. Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004;22:3868–76.

    Article  PubMed  Google Scholar 

  15. Fizazi K, Pagliaro L, Laplanche A, et al. Personalized chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15:1442–50.

    Article  CAS  PubMed  Google Scholar 

  16. Massard C, Kramar A, Beyer J, et al. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol. 2013;24:322–8.

    Article  CAS  PubMed  Google Scholar 

  17. Fizazi K, Culine S, Droz JP, et al. Primary mediastinal non-seminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy. J Clin Oncol. 1998;16:725–32.

    CAS  PubMed  Google Scholar 

  18. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. J Natl Cancer Inst. 1999;91:839–46.

    Article  CAS  PubMed  Google Scholar 

  19. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30:800–5.

    Article  CAS  PubMed  Google Scholar 

  20. Massard C, Plantade A, Gross-Goupil M, et al. Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol. 2010;21:1585–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karim Fizazi MD, PhD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fizazi, K., Culine, S. (2015). Poor-Prognosis Germ Cell Tumours. In: Krege, S. (eds) Diagnosis and Management of Testicular Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-17467-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17467-9_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17466-2

  • Online ISBN: 978-3-319-17467-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics